LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: a systematic review and meta-analysis

We conducted a systematic review and meta-analysis to investigate the clinical values, including clinicopathology, prognosis, and diagnosis of different long non-coding RNAs (lncRNAs) in renal cell carcinoma (RCC). A total of 14 eligible studies, including 10 on clinicopathological features, 11 on p...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-11, Vol.7 (45), p.74325-74336
Main Authors: Chen, Jianwen, Chen, Yalei, Gu, Liangyou, Li, Xintao, Gao, Yu, Lyu, Xiangjun, Chen, Luyao, Luo, Guoxiong, Wang, Lei, Xie, Yongpeng, Duan, Junyao, Peng, Cheng, Ma, Xin
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - genetics
Carcinoma, Renal Cell - genetics
Carcinoma, Renal Cell - pathology
Clinical Research Paper
Humans
Kidney Neoplasms - genetics
Prognosis
RNA, Long Noncoding - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We conducted a systematic review and meta-analysis to investigate the clinical values, including clinicopathology, prognosis, and diagnosis of different long non-coding RNAs (lncRNAs) in renal cell carcinoma (RCC). A total of 14 eligible studies, including 10 on clinicopathological features, 11 on prognosis, and 3 on diagnosis were identified. Results revealed that metastasis-associated lung adenocarcinoma transcript 1(MALAT1) expression was associated with tumor stage (odds ratio [OR], 3.46; 95% confidence interval [CI], 1.63-7.36; p=0.001). The high expression of MALAT1 could be considered a biomarker of the early detection of lymph node metastasis and predictor of poor survival in RCC patients, who likely manifested short overall survival (OS; hazard ratio [HR], 2.97; 95% CI, 1.68-5.28; p
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.11101